137 related articles for article (PubMed ID: 29730354)
41. The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
Mitra A; Sasikumar K; Parthasaradhi BV; Radha V
Biochim Biophys Acta; 2013 Jan; 1832(1):275-84. PubMed ID: 23124138
[TBL] [Abstract][Full Text] [Related]
42. Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase.
Aleem SU; Craddock BP; Miller WT
PLoS One; 2015; 10(6):e0131062. PubMed ID: 26090675
[TBL] [Abstract][Full Text] [Related]
43. Suppression of RUNX1 by siRNA in megakaryocytic UT-7/GM cells.
Okada Y; Nagai R; Matsuura E; Hoshika Y; Nakata E; Nagura H; Watanabe A; Komatsu N; Doi T
Nucleic Acids Symp Ser (Oxf); 2006; (50):261-2. PubMed ID: 17150917
[TBL] [Abstract][Full Text] [Related]
44. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
Huang G; Zhang P; Hirai H; Elf S; Yan X; Chen Z; Koschmieder S; Okuno Y; Dayaram T; Growney JD; Shivdasani RA; Gilliland DG; Speck NA; Nimer SD; Tenen DG
Nat Genet; 2008 Jan; 40(1):51-60. PubMed ID: 17994017
[TBL] [Abstract][Full Text] [Related]
45. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.
Antony-Debré I; Bluteau D; Itzykson R; Baccini V; Renneville A; Boehlen F; Morabito M; Droin N; Deswarte C; Chang Y; Leverger G; Solary E; Vainchenker W; Favier R; Raslova H
Blood; 2012 Sep; 120(13):2719-22. PubMed ID: 22677128
[TBL] [Abstract][Full Text] [Related]
46. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.
Jalagadugula G; Mao G; Kaur G; Goldfinger LE; Dhanasekaran DN; Rao AK
Blood; 2010 Dec; 116(26):6037-45. PubMed ID: 20876458
[TBL] [Abstract][Full Text] [Related]
47. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
48. Posttranslational modifications of RUNX1 as potential anticancer targets.
Goyama S; Huang G; Kurokawa M; Mulloy JC
Oncogene; 2015 Jul; 34(27):3483-92. PubMed ID: 25263451
[TBL] [Abstract][Full Text] [Related]
49. c-Abl regulates proteasome abundance by controlling the ubiquitin-proteasomal degradation of PSMA7 subunit.
Li D; Dong Q; Tao Q; Gu J; Cui Y; Jiang X; Yuan J; Li W; Xu R; Jin Y; Li P; Weaver DT; Ma Q; Liu X; Cao C
Cell Rep; 2015 Feb; 10(4):484-96. PubMed ID: 25620702
[TBL] [Abstract][Full Text] [Related]
50. Dysregulation of NIPBL leads to impaired RUNX1 expression and haematopoietic defects.
Mazzola M; Pezzotta A; Fazio G; Rigamonti A; Bresciani E; Gaudenzi G; Pelleri MC; Saitta C; Ferrari L; Parma M; Fumagalli M; Biondi A; Cazzaniga G; Marozzi A; Pistocchi A
J Cell Mol Med; 2020 Jun; 24(11):6272-6282. PubMed ID: 32323916
[TBL] [Abstract][Full Text] [Related]
51. Altered platelet-megakaryocyte endocytosis and trafficking of albumin and fibrinogen in RUNX1 haplodeficiency.
Del Carpio-Cano F; Mao G; Goldfinger LE; Wurtzel J; Guan L; Alam MA; Lee K; Poncz M; Rao AK
Blood Adv; 2024 Apr; 8(7):1699-1714. PubMed ID: 38330198
[TBL] [Abstract][Full Text] [Related]
52. Nuclear c-Abl is a COOH-terminal repeated domain (CTD)-tyrosine (CTD)-tyrosine kinase-specific for the mammalian RNA polymerase II: possible role in transcription elongation.
Baskaran R; Escobar SR; Wang JY
Cell Growth Differ; 1999 Jun; 10(6):387-96. PubMed ID: 10392900
[TBL] [Abstract][Full Text] [Related]
53. The tyrosine kinase c-Abl protects c-Jun from ubiquitination-mediated degradation in T cells.
Gao B; Lee SM; Fang D
J Biol Chem; 2006 Oct; 281(40):29711-8. PubMed ID: 16901904
[TBL] [Abstract][Full Text] [Related]
54. Dynamic combinatorial interactions of RUNX1 and cooperating partners regulates megakaryocytic differentiation in cell line models.
Pencovich N; Jaschek R; Tanay A; Groner Y
Blood; 2011 Jan; 117(1):e1-14. PubMed ID: 20959602
[TBL] [Abstract][Full Text] [Related]
55. GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro.
Ono M; Matsubara Y; Shibano T; Ikeda Y; Murata M
Platelets; 2011; 22(3):196-203. PubMed ID: 21231855
[TBL] [Abstract][Full Text] [Related]
56. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
57. Identification and functional analysis of a new phosphorylation site (Y398) in the SH3 domain of Abi-1.
Sato M; Maruoka M; Yokota N; Kuwano M; Matsui A; Inada M; Ogawa T; Ishida-Kitagawa N; Takeya T
FEBS Lett; 2011 Mar; 585(6):834-40. PubMed ID: 21320496
[TBL] [Abstract][Full Text] [Related]
58. A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1.
Plattner R; Irvin BJ; Guo S; Blackburn K; Kazlauskas A; Abraham RT; York JD; Pendergast AM
Nat Cell Biol; 2003 Apr; 5(4):309-19. PubMed ID: 12652307
[TBL] [Abstract][Full Text] [Related]
59. Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR in RUNX1 deficiency.
Jalagadugula G; Mao G; Goldfinger LE; Wurtzel J; Del Carpio-Cano F; Lambert MP; Estevez B; French DL; Poncz M; Rao AK
Blood Adv; 2022 Sep; 6(17):5100-5112. PubMed ID: 35839075
[TBL] [Abstract][Full Text] [Related]
60. Megakaryocytic programming by a transcriptional regulatory loop: A circle connecting RUNX1, GATA-1, and P-TEFb.
Goldfarb AN
J Cell Biochem; 2009 Jun; 107(3):377-82. PubMed ID: 19350569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
